PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
The hold will likely delay trial results, and scientists say the pause is proof that safety protocols in clinical trials are working as they should.
The hold will likely delay trial results, and scientists say the pause is proof that safety protocols in clinical trials are working as they should.
